As­traZeneca read­ies April EUA fil­ing with 79% vac­cine ef­fi­ca­cy, first glimpse of el­der­ly da­ta and 100% pro­tec­tion against se­vere dis­ease in US tri­al

Weeks in­to a chaot­ic vac­cine roll­out in Eu­rope, As­traZeneca fi­nal­ly has the long-await­ed Phase III da­ta it needs to crack open the Amer­i­can mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.